Latest newsCANCER VACCINE COMPANY BIOMIRA EXERCISES RIGHTS IN...

Latest news
CANCER VACCINE COMPANY BIOMIRA EXERCISES RIGHTS IN PRIMA
Melbourne, Australia. 18 July 2005 Prima Biomed (ASX:PRR, “Prima”) announced today that
Canadian-based cancer vaccine company Biomira Inc (NASDAQ:BIOM/TSX: BRA), has exercised its
Put Option to take up equity in Prima which results in Biomira holding approx.1.62% equity stake in
Prima.
Biomira’s investment in Prima is being conducted through a Put Option which will convert Biomira's
equity in the company's subsidiary company CancerVac Pty Ltd into Prima ordinary shares. As a
result, Prima will own 86.55% of the CancerVac subsidiary.
"Biomira is undoubtedly a leader in the development of cancer immunotherapy. Biomira’s election to
take up Prima’s shares is a demonstration of the value Biomira places in Prima’s diverse portfolio and
potential of our approach to developing a vaccine for cancer," said Mr Eugene Kopp, Executive
Chairman of Prima.
"Biomira is a significant partner for Prima and its election is an endorsement for the long term strategy
of the company."
Prima and Biomira are currently collaborating to develop an immunotherapy for cancer. Prima
acquired a world wide exclusive licence from Biomira for the tumour antigen mucin 1 in ex vivo cancer
immunotherapy.
Biomira holds commercialisation rights over Prima’s technology in its subsidiary CancerVac which is
finalising recruitment in a Phase IIa ovarian cancer clinical trial. Patients in the trial are administered
the mucin 1 to stimulate immune responses to the tumours.
About Biomira Inc
Biomira is a biotechnology company, based in Edmonton, Canada specialising in the development of
innovative therapeutic approaches to cancer management. Biomira’s commitment to the treatment of
cancer currently focuses on the development of vaccines containing synthetic antigens and novel
strategies for cancer immunotherapy.
About Prima Biomed Ltd
Prima Biomed (ASX: PRR) is a biotechnology company based in Melbourne and is developing
technologies in the fields of immunology and cancer immunotherapy originating from the Austin
Research Institute in Melbourne, Australia.
For further information, visit www.primabiomed.com.au
Company Contacts:
Company Enquiries Mr Eugene Kopp 03 9854 5700
Media Enquiries Rebecca Wilson 0417 382 391
This release may contain forward-looking statements. Various factors could cause actual results to
differ materially from those projected in forward-looking statements, including those predicting the
timing and results of clinical trials, interpretation and implications of such results, availability or
adequacy of financing, the sales and marketing of commercial products or the efficacy of products.
Although the Company believes that the forward - looking statements contained herein are
reasonable, it can give no assurance that the Company’s expectations are correct. All forward -
looking statements are expressly qualified in their entirety by this cautionary statement.